This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world
Journal of Cancer Research and Clinical Oncology Open Access 08 April 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature https://doi.org/10.1038/s41586-021-04161-3 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. Pembrolizumab for HER2+ gastric cancer. Nat Rev Clin Oncol 19, 150 (2022). https://doi.org/10.1038/s41571-021-00594-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00594-x
This article is cited by
-
Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world
Journal of Cancer Research and Clinical Oncology (2024)